Selinexor (KPT-330)
KCP-330-006
Phase 2 small_molecule terminated
Quick answer
Selinexor (KPT-330) for Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated